Menu

Company Offers Free Whole-Genome Sequencing for Data Sharers

Nebula Genomics is among the first blockchain-based companies to reward users for contributing personal data for research.

Nov 15, 2018
Shawna Williams

ABOVE: © ISTOCK.COM, POLESNOY

Fifteen years ago, the first sequencing of a human genome was declared complete, at a cost of about $2.7 billion. While the price tag for whole-genome sequencing has fallen considerably since then, it’s still far less affordable than typical direct-to-consumer genetic tests, which analyze hundreds of thousands of telling sites in the genome, rather than sifting through all 3 billion of its base pairs. A platform, announced by the company Nebula Genomics, now aims to change that by connecting individuals with researchers who will pay for the genome sequencing in exchange for a look at the results.

“This is the first step in realizing a world in which individuals control and are compensated for use of their genetic data by medical researchers,” Nebula cofounder George Church, who is also a geneticist at Harvard Medical School and MIT, says in a press release sent to The Scientist. “Nebula will produce the data researchers have been waiting for in their search for curative breakthroughs, higher rates of disease prevention, and dramatic advances in personalized medicine.”

See “First Blockchain-based Genomic Data Marketplace Launches

With the announcement, Nebula joins EncrypGen, which launched its platform last week, in the marketplace of companies using blockchain-based technology to enable secure access to genomic data. Both aim to reward individuals for sharing their genetic and health-related information for use in studies. EncrypGen does not itself offer genetic testing, but users can upload data from testing services or buy a SNP-based test from one of its partners. EncrypGen’s cofounder and CEO, David Koepsell, writes in an email to The Scientist that the company plans to offer whole-genome testing through a partner on its website soon, and that he expects users will be able to subsidize its $1,500 cost with tokens earned through the platform.

This summer, Alta Charo, a bioethicist at the University of Wisconsin Law School in Madison, told The Scientist that selling access to genetic information isn’t so radical in an era when we already “monetize our privacy in many ways.” The new breed of blockchain-based platforms, she added, provides individuals with “potentially more opportunities to have very specific control over what’s given out and in what specific form.”

See “Startups Plan the Health Data Gold Rush

December 2018

Invisible Borders

An emerging appreciation for membraneless organelles and the liquid dynamics that shape them

Marketplace

Sponsored Product Updates

SYNENTEC Nearly Doubles Throughput with its New Automated Cell Imager
SYNENTEC Nearly Doubles Throughput with its New Automated Cell Imager
SYNENTEC GmbH, the German manufacturer of automated cell imagers, has launched its latest generation of CELLAVISTA® imagers: CELLAVISTA® 4.
Introducing The Ingenio® EZporator® Electroporation System from The Experts in Transfection
Introducing The Ingenio® EZporator® Electroporation System from The Experts in Transfection
Recognized as the leader in nucleic acid delivery technologies, Mirus Bio announces the first instrument added to their product portfolio, the Ingenio® EZporator® Electroporation System.
Streamlining the workflow with INTEGRA’s VIAFLO 96/384
Streamlining the workflow with INTEGRA’s VIAFLO 96/384
Researchers at the University of Zurich in Switzerland are using INTEGRA’s VIAFLO 96/384 multichannel electronic pipette to streamline the experimental workflow of studies on Pseudomonas aeruginosa – a bacterium that commonly infects individuals with lung conditions, such as cystic fibrosis.
Rapid ELISA-Based Measurement Of Protein Phosphorylation
Rapid ELISA-Based Measurement Of Protein Phosphorylation
In this article, RayBiotech will present a study in which the phosphorylation of two proteins, STAT1 (Tyr701) and Mek1 (Ser217/221), is detected in response to various agonists. Data from the RayBio® Phosphorylation ELISA kits will be compared to traditional immunoblotting.